Patent US1989419A successfully refreshed from Google Patents.
US4416893A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted 1,2,5-oxadiazole-2-oxides in human cardiovascular system disease
Assignee: Sanofi Aventis Deutschland GmbH
•
Filing: 1981-03-24
•
Granted: 1983-11-22
•
Expires: 2001-03-24
Abstract
Abstract Pharmaceutical compositions comprising as pharmacologically active component a 1,2,5-oxadiazole-2-oxide of the general formula I ##STR1## wherein R 1 and R 2 have the following meaning: ______________________________________ R 1 R 2 ______________________________________ 1. CO--NH 2 CH 3 2. COOC 2 H 5 CH 3 3. CO--NHNH 2 CH 3 4. COOH CH 3 5. --NH--COOC 2 H 5 CH 3 6. --NH--COOC 3 H 7 (n) CH 3 7. --NH--COOC 3 H 7 (i) CH 3 8. --NH--COOC 4 H 9 (n) CH 3 9. --NH--COOCH 2 --phenyl CH 3 10. CO--NH 2 CO--NH 2 11. CN CN 12. COOH COOCH 3 13. COOCH 3 COOCH 3 14. COOC 2 H 5 COOC 2 H 5 15. CH 3 CO--NH 2 16. CH 3 COOC 2 H 5 17. CH 3 CO--NHNH 2 18. CH 3 COOH 19. CN CO--NH 2 20. CO--NH--phenyl CO--NH--phenyl 21. CH 3 NH--COOC 2 H 5 22. CH 3 NH--COOC 3 H 7 (n) 23. CH 3 NH--COOC 3 H 7 (i) 24. CH 3 NH--COOC 4 H 9 (n) 25. CH 3 NH--COOCH 2 --phenyl 26. CO--NH--phenyl CH 3 or CH 3 CO--NH--phenyl ______________________________________ They are useful for treating or preventing cardiovascular system disease in man.
Inventors
- 👤 Karl Schonafinger
- 👤 Rudi Beyerle
- 👤 Anton Mogilev
- 👤 Helmut Bohn
- 👤 Piero Martorana
- 👤 Rolf-Eberhard Nitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 11:25
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61P; A61P9/00; A61P9/08; A61P9/10; A61P9/12; C; C07; C07D; C07D271/00; C07D271/02; C07D271/08
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
58 words
A pharmaceutical composition useful for treating or preventing human cardiovascular-system disease and comprising a pharmacologically-active component and physiologically-acceptable pharmacologically-inert excipient, the pharmacologically-active component comprising from 0.01 to 20 percent by weight, based on the total composition weight, of a 1,2,5-oxadiazole-2-oxide having the structure of (a) the 3-methyl ester of 1,2,5-oxadiazole-2-oxide-3,4-dicarboxylic acid, (b) 3-methyl-1,2,5-oxadiazole-2-oxide-4-carboxylic acid-anilide or (c) 4-methyl-1,2,5-oxadiazole-2-oxide-3-carboxylic acid-anilide.
Claim 2
Dependent Claim
58 words
A pharmaceutical composition useful for treating or preventing human cardiovascular-system disease and comprising a pharmacologically-active component and physiologically-acceptable pharmacologically-inert excipient, the pharmacologically-active component comprising from 0.01 to 20 percent by weight, based on the total composition weight, of a 1,2,5-oxadiazole-2-oxide having the structure of (a) the 3-methyl ester of 1,2,5-oxadiazole-2-oxide-3,4-dicarboxylic acid, (b) 3-methyl-1,2,5-oxadiazole-2-oxide-4-carboxylic acid-anilide or (c) 4-methyl-1,2,5-oxadiazole-2-oxide-3-carboxylic acid-anilide.
Claim 3
Dependent Claim
22 words
A pharmaceutical composition according to claim 1 comprising, per unit dose, from 0.1 to 100 milligrams of the 3-methylester of 1,2,5-oxadiazole-2-oxide-3,4-dicarboxylic acid.
Claim 4
Dependent Claim
16 words
A pharmaceutical composition according to claim 1 wherein the 1,2,5-oxadiazole has the structure of 3-methyl-1,2,5-oxadiazole-2-oxide-4-carboxylic acid-anilide.
Claim 5
Dependent Claim
16 words
A pharmaceutical composition according to claim 1 wherein the 1,2,5-oxadiazole has the structure of 4-methyl-1,2,5-oxadiazole-2-oxide-3-carboxylic acid-anilide.
Claim 6
Independent Claim
176 words
A method of treating or preventing cardiovascular system disease which comprises administering to a human, subject to or afflicted with such disease, an effective amount of a pharmaceutical composition comprising a pharmacologically-active component and physiologically-acceptable pharmacologically-inert excipient, the pharmacologically-active component comprising from 0.01 to 20 percent by weight, based on the total composition weight, of 1,2,5-oxadiazole-2-oxide of formula I ##STR5## wherein R 1 and R 2 have the following meaning: ______________________________________
R.sup.1 R.sup.2
______________________________________
1. CO--NH.sub.2 CH.sub.3
2. COOC.sub.2 H.sub.5
CH.sub.3
3. CO--NHNH.sub.2 CH.sub.3
4. COOH CH.sub.3
5. --NH--COOC.sub.2 H.sub.5
CH.sub.3
6. --NH--COOC.sub.3 H.sub.7 (n)
CH.sub.3
7. --NH--COOC.sub.3 H.sub.7 (i)
CH.sub.3
8. --NH--COOC.sub.4 H.sub.9 (n)
CH.sub.3
9. --NH--COOCH.sub.2 --phenyl
CH.sub.3
10. CO--NH.sub.2 CO--NH.sub.2
11. CN CN
12. COOH COOCH.sub.3
13. COOCH.sub.3 COOCH.sub.3
14. COOC.sub.2 H.sub.5
COOC.sub.2 H.sub.5
15. CH.sub.3 CO--NH.sub.2
16. CH.sub.3 COOC.sub.2 H.sub.5
17. CH.sub.3 CO--NHNH.sub.2
18. CH.sub.3 COOH
19. CN CO--NH.sub.2
20. CO--NH--phenyl CO--NH--phenyl
21. CH.sub.3 NH--COOC.sub.2 H.sub.5
22. CH.sub.3 NH--COOC.sub.3 H.sub.7 (n)
23. CH.sub.3 NH--COOC.sub.3 H.sub.7 (i)
24. CH.sub.3 NH--COOC.sub.4 H.sub.9 (n)
25. CH.sub.3 NH--COOCH.sub.2 --phenyl
26. CO--NH--phenyl CH.sub.3 or
CH.sub.3 CO--NH--phenyl
______________________________________
Claim 7
Independent Claim
176 words
A method of treating or preventing cardiovascular system disease which comprises administering to a human, subject to or afflicted with such disease, an effective amount of a pharmaceutical composition comprising a pharmacologically-active component and physiologically-acceptable pharmacologically-inert excipient, the pharmacologically-active component comprising from 0.01 to 20 percent by weight, based on the total composition weight, of 1,2,5-oxadiazole-2-oxide of formula I ##STR5## wherein R 1 and R 2 have the following meaning: ______________________________________
R.sup.1 R.sup.2
______________________________________
1. CO--NH.sub.2 CH.sub.3
2. COOC.sub.2 H.sub.5
CH.sub.3
3. CO--NHNH.sub.2 CH.sub.3
4. COOH CH.sub.3
5. --NH--COOC.sub.2 H.sub.5
CH.sub.3
6. --NH--COOC.sub.3 H.sub.7 (n)
CH.sub.3
7. --NH--COOC.sub.3 H.sub.7 (i)
CH.sub.3
8. --NH--COOC.sub.4 H.sub.9 (n)
CH.sub.3
9. --NH--COOCH.sub.2 --phenyl
CH.sub.3
10. CO--NH.sub.2 CO--NH.sub.2
11. CN CN
12. COOH COOCH.sub.3
13. COOCH.sub.3 COOCH.sub.3
14. COOC.sub.2 H.sub.5
COOC.sub.2 H.sub.5
15. CH.sub.3 CO--NH.sub.2
16. CH.sub.3 COOC.sub.2 H.sub.5
17. CH.sub.3 CO--NHNH.sub.2
18. CH.sub.3 COOH
19. CN CO--NH.sub.2
20. CO--NH--phenyl CO--NH--phenyl
21. CH.sub.3 NH--COOC.sub.2 H.sub.5
22. CH.sub.3 NH--COOC.sub.3 H.sub.7 (n)
23. CH.sub.3 NH--COOC.sub.3 H.sub.7 (i)
24. CH.sub.3 NH--COOC.sub.4 H.sub.9 (n)
25. CH.sub.3 NH--COOCH.sub.2 --phenyl
26. CO--NH--phenyl CH.sub.3 or
CH.sub.3 CO--NH--phenyl
______________________________________
Claim 8
Independent Claim
75 words
A method of treating or preventing high blood pressure or angina pectoris which comprises administering to a human, subject to or afflicted with one or both of such conditions, an effective amount of a pharmaceutical composition comprising a pharmacologically-active component and physiologically-acceptable pharmacologically-inert excipient, the pharmacologically-active component comprising from 0.01 to 20 percent by weight, based on the total composition weight, of (a) 3-methyl-1,2,5-oxadiazole-2-oxide-4-carboxylic acid amide, (b) 4-methyl-1,2,5-oxadiazole-2-oxide-3-carboxylic acid amide or (c) 1,2,5-oxadiazole-2-oxide-3,4-dicarboxylic acid diamide.
Claim 9
Independent Claim
75 words
A method of treating or preventing high blood pressure or angina pectoris which comprises administering to a human, subject to or afflicted with one or both of such conditions, an effective amount of a pharmaceutical composition comprising a pharmacologically-active component and physiologically-acceptable pharmacologically-inert excipient, the pharmacologically-active component comprising from 0.01 to 20 percent by weight, based on the total composition weight, of (a) 3-methyl-1,2,5-oxadiazole-2-oxide-4-carboxylic acid amide, (b) 4-methyl-1,2,5-oxadiazole-2-oxide-3-carboxylic acid amide or (c) 1,2,5-oxadiazole-2-oxide-3,4-dicarboxylic acid diamide.
Claim 10
Dependent Claim
19 words
A method according to claim 6 wherein the pharmaceutical composition has an effective amount per unit dose of (a).
Claim 11
Dependent Claim
19 words
A method according to claim 6 wherein the pharmaceutical composition has an effective amount per unit dose of (b).
Claim 12
Dependent Claim
19 words
A method according to claim 6 wherein the pharmaceutical composition has an effective amount per unit dose of (c).
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-11-21 | 1987-05-23 | 1987-11-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-11-21 | 1991-05-23 | 1991-11-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-11-21 | 1995-05-23 | 1995-11-22 | $7700.00 | Window Closed / Lapsed |